Classic Style Guide,OZEM

The burgeoning field of weight loss drugs, particularly those leveraging GLP-1 agonists, represents a significant and rapidly evolving sector within the pharmaceutical industry. For investors looking to gain exposure to this innovative space, the Roundhill GLP-1 & Weight Loss ETF (ticker: OZEM) offers a focused approach. This ETF aims to capitalize on the potential for capital appreciation by investing in companies actively involved in the development and commercialization of GLP-1 and other weight management drugs.

Launched as the world's first ETF dedicated to the GLP-1 sector, OZEM seeks to provide investors with a diversified portfolio of global companies at the forefront of this medical revolution. The fund's investment objective is to achieve capital appreciation, with managers typically investing at least 80% of its net assets in companies engaged in this specific industry. This strategic allocation ensures a concentrated bet on the growth trajectory of weight loss solutions.

Understanding the OZEM ETF and its Holdings

The Roundhill GLP-1 & Weight Loss ETF (often referred to by its ticker OZEM) targets the global weight management industry. Its portfolio includes companies that are instrumental in the research, development, and distribution of groundbreaking treatments. While specific holdings will fluctuate, the ETF is designed to capture the growth of companies involved with GLP-1 agonists and other innovative weight loss therapies. Investors can review a detailed OZEM holdings list to understand the specific companies and their weighting within the fund. For instance, recent data indicates the OZEM stock price today is 30.83.

The Roundhill Glp-1 & Weight Loss ETF OZEM is actively managed, distinguishing it from passive investment strategies. This active approach allows the fund managers to make strategic decisions regarding company selection and portfolio adjustments in response to market dynamics and scientific advancements within the weight loss and pharmaceutical sectors. This can be contrasted with passive approaches, offering a different investment philosophy for those interested in the GLP-1 ETF landscape.

Key Features and Investment Considerations for OZEM

When considering an investment in OZEM, several key parameters and details are crucial for informed decision-making. The Roundhill GLP-1 & Weight Loss ETF price can be tracked through various financial platforms, with recent quotes showing variations. For example, on April 23, 2026, the OZEM price was reported at $31.19, with a change of $0.29 (0.92%). Another snapshot on April 24, 2026, indicated a price of $31.36 USD. The OZEM expense ratio is 0.59%, which is a factor to consider when evaluating the overall cost of investing in the ETF.

The Roundhill GLP-1 & Weight Loss ETF (OZEM) also has a trailing yield of 1.32%, which is noted as being above the category average of 1.18%. The fund typically distributes its income annually. For those interested in the financial performance, historical data like the Roundhill Glp-1 & Weight Loss ETF OZEM NAV (Net Asset Value) of 31.38 and a 1-day return of 0.34% provide further insights. Total assets for OZEM stand at approximately 52.1 million.

How to Invest in the Roundhill GLP-1 & Weight Loss ETF

For individuals interested in buying the Roundhill GLP-1 & Weight Loss ETF (OZEM), several brokerage platforms facilitate these transactions. For instance, one can learn how to buy Roundhill Glp-1 & Weight Loss ETF (OZEM) stocks on Kraken starting with a minimum of $10, utilizing various payment methods like debit cards, ACH deposits, or Apple/Google Pay. Other platforms also offer access to buying Roundhill Glp-1 & Weight Loss ETF shares, with resources available to guide investors through the process, including information on related fees and trading tips.

The Roundhill Investments firm, behind the OZEM ETF, is dedicated to providing investors with access to innovative and rapidly growing market sectors. The Roundhill GLP-1 & Weight Loss ETF is a testament to this commitment, offering a specialized avenue to invest in what is considered one of the most revolutionary advancements in weight loss and metabolic health. The Roundhill approach is to identify high-potential sectors and create focused investment vehicles like OZEM.

The Significance of GLP-1 Agonists in Weight Management

The growing importance of GLP-1 agonists cannot be overstated. These drugs have demonstrated significant efficacy in aiding weight loss and managing conditions like type 2 diabetes. Companies involved in their development, including Eli Lilly, have seen substantial market growth, with some stocks experiencing significant appreciation. The Roundhill GLP-1 & Weight Loss ETF (OZEM), by investing in such companies, may have significant exposure to the pharmaceutical companies